Perspective Therapeutics, Inc. announced that its Phase 1/2a clinical trial for [212Pb]VMT-α-NET is moving into Cohort 3, administering a higher fixed dose of 6 mCi for patients with unresectable or ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results